NO20080244L - Doseringsstyring for prasugrel - Google Patents

Doseringsstyring for prasugrel

Info

Publication number
NO20080244L
NO20080244L NO20080244A NO20080244A NO20080244L NO 20080244 L NO20080244 L NO 20080244L NO 20080244 A NO20080244 A NO 20080244A NO 20080244 A NO20080244 A NO 20080244A NO 20080244 L NO20080244 L NO 20080244L
Authority
NO
Norway
Prior art keywords
prasugrel
dosage control
pharmaceutically acceptable
acceptable salt
dosage regimen
Prior art date
Application number
NO20080244A
Other languages
English (en)
Norwegian (no)
Inventor
Joseph Anthony Jakubowski
John Thomas Brandt
Nagy Alphonse Farid
Christopher David Payne
Govinda Jayanath Weerakkody
Kenneth John Winters
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20080244L publication Critical patent/NO20080244L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20080244A 2005-06-17 2008-01-14 Doseringsstyring for prasugrel NO20080244L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17
PCT/US2006/023006 WO2006138317A2 (en) 2005-06-17 2006-06-13 Dosage regimen for prasugrel

Publications (1)

Publication Number Publication Date
NO20080244L true NO20080244L (no) 2008-01-14

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080244A NO20080244L (no) 2005-06-17 2008-01-14 Doseringsstyring for prasugrel

Country Status (18)

Country Link
US (1) US20090156632A1 (enExample)
EP (1) EP1893205A4 (enExample)
JP (1) JP2008543853A (enExample)
KR (1) KR20080016647A (enExample)
CN (1) CN101198329A (enExample)
AU (1) AU2006259538A1 (enExample)
BR (1) BRPI0612624A2 (enExample)
CA (1) CA2612315A1 (enExample)
EA (1) EA200800075A1 (enExample)
EC (1) ECSP078014A (enExample)
GT (1) GT200600263A (enExample)
IL (1) IL187486A0 (enExample)
MA (1) MA29722B1 (enExample)
MX (1) MX2007015430A (enExample)
NO (1) NO20080244L (enExample)
TN (1) TNSN07474A1 (enExample)
WO (1) WO2006138317A2 (enExample)
ZA (1) ZA200710769B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101647842B1 (ko) * 2006-12-07 2016-08-11 다이이찌 산쿄 가부시키가이샤 저장 안정성이 개선된 의약 조성물
EP2100610A4 (en) 2006-12-07 2009-12-02 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION WITH LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE
RU2470636C2 (ru) 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
ES2769949T3 (es) 2009-05-13 2020-06-29 Cydex Pharmaceuticals Inc Composiciones farmacéuticas que comprenden prasugrel y derivados de ciclodextrina y métodos de preparación y uso de las mismas
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
WO2016203018A1 (en) 2015-06-19 2016-12-22 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
KR20030014294A (ko) * 2000-07-06 2003-02-15 상꾜 가부시키가이샤 히드로피리딘 유도체 산부가염
PL206138B1 (pl) * 2000-12-25 2010-07-30 Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
WO2004098713A2 (en) * 2003-05-05 2004-11-18 Eli Lilly And Company Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4)

Also Published As

Publication number Publication date
EP1893205A4 (en) 2010-06-30
MA29722B1 (fr) 2008-09-01
TNSN07474A1 (en) 2009-03-17
EA200800075A1 (ru) 2008-04-28
CA2612315A1 (en) 2006-12-28
JP2008543853A (ja) 2008-12-04
ECSP078014A (es) 2008-01-23
AU2006259538A1 (en) 2006-12-28
MX2007015430A (es) 2008-02-21
ZA200710769B (en) 2009-09-30
KR20080016647A (ko) 2008-02-21
WO2006138317A3 (en) 2007-05-03
WO2006138317A2 (en) 2006-12-28
EP1893205A2 (en) 2008-03-05
US20090156632A1 (en) 2009-06-18
GT200600263A (es) 2007-02-23
IL187486A0 (en) 2008-06-05
BRPI0612624A2 (pt) 2016-11-29
CN101198329A (zh) 2008-06-11

Similar Documents

Publication Publication Date Title
NO20080244L (no) Doseringsstyring for prasugrel
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
JP2015524444A5 (enExample)
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
NO20055880L (no) Memantin orale doseringsformer
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
AR036312A1 (es) Composicion farmaceutica
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
AU2018329496A1 (en) Sublingual epinephrine tablets
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
PL1778209T3 (pl) Sposoby i kompozycje do doustnego dostarczania FTS
NZ703464A (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
US20070292529A1 (en) Strontium compositions and methods of treating osteoporotic conditions
TW200626133A (en) Oral medication for twice-daily administration
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
CN101396561A (zh) 含有acei的组合物在制备治疗高同型半胱氨酸血症损伤及其相关疾病的药物中的用途
US20190381034A1 (en) Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
WO2007074170A3 (en) Compositions and methods for the treatment and prevention of disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application